The WHO Pandemic Agreement: A Guide to the New Global Health Treaty, 'One Health,' and the Pathogen Access Debate

In May 2025, the World Health Assembly achieved something it had not managed in over two decades: the adoption of a legally binding international health treaty. Born from the collective trauma of the COVID-19 crisis, the WHO Pandemic Agreement aims to fundamentally rewire how the world prepares for and responds to global health emergencies. The treaty represents a monumental shift from ad hoc, reactive crisis management to institutionalized global governance, aiming to ensure that the catastrophic failures of the early 2020s are never repeated.[2][3]

The agreement was designed to directly address the systemic inequities, fragmented supply chains, and vaccine nationalism that defined the early years of the COVID-19 pandemic. That crisis ultimately claimed an estimated 20 million lives globally, overwhelmed health systems on every continent, and erased roughly $13 trillion in global economic output. By establishing clear, legally binding rules of the road before the next novel virus emerges, the treaty seeks to create a framework built on equity, solidarity, and rapid scientific collaboration. It is only the second binding health treaty in the WHO’s 77-year history, following the 2003 Framework Convention on Tobacco Control.[2]

However, more than a year after its historic adoption by consensus, the agreement remains in a precarious holding pattern. While the overarching framework was approved by 124 nations, the treaty cannot officially open for signature or ratification until member states finalize a highly contentious annex known as the Pathogen Access and Benefit-Sharing (PABS) system. This annex contains the precise legal and logistical details of how countries will share data and medical supplies, and negotiations over its terms have repeatedly stalled due to deep geopolitical divisions.[1][2]

The urgency to break this deadlock reached a peak in June 2026, when WHO Director-General Tedros Adhanom Ghebreyesus and Brazilian President Luiz Inácio Lula da Silva issued an urgent joint letter calling on world leaders to finalize the agreement. They set a firm deadline of July 17, 2026, to complete the PABS annex, warning that further delays risk leaving the world dangerously exposed to the next biological threat. The letter underscored that shifting environmental factors and advances in biotechnology mean the next pandemic is a matter of when, not if.

To understand the stakes of the current negotiations and what the treaty actually does, it is necessary to examine its two foundational pillars. The first is a comprehensive commitment to upstream prevention through what scientists call the 'One Health' approach. This represents a paradigm shift in international law, moving away from treating human disease in a vacuum and instead acknowledging the ecological drivers of pandemics. The treaty formally recognizes that the health of humans, domestic animals, wildlife, and the broader environment are inextricably linked, and that protecting one requires protecting them all.[2]

Historically, global health frameworks have neglected the animal-human interface, focusing almost entirely on containing outbreaks after they have already begun spreading among people. Yet, approximately 75 percent of all emerging infectious diseases—including SARS, H1N1, Ebola, and COVID-19—originate from zoonotic spillovers, where viruses jump from animal hosts to humans. The Pandemic Agreement tackles this reality head-on by requiring governments to address the root drivers of disease emergence. Article 5 of the treaty mandates that signatory nations establish multisectoral surveillance systems that break down the traditional silos between different scientific disciplines.[2]

Under these One Health provisions, countries must integrate data from veterinary clinics, wildlife monitoring programs, and human hospitals to detect novel pathogens before they can trigger a global outbreak. The agreement also calls for stricter monitoring of high-risk environmental interfaces, such as wildlife markets, areas of rapid deforestation, and intensive agricultural operations where humans and animals live in close proximity. By identifying a dangerous virus while it is still circulating in animal populations, global health authorities hope to extinguish potential pandemics at their source, long before they require border closures or mass quarantines.[2]

While the One Health provisions focus on prevention, the second pillar—the PABS system—focuses on equity and response. This is the mechanism currently stalling the treaty's implementation, as it attempts to balance the rapid sharing of scientific data with the equitable distribution of medical countermeasures. The PABS system is designed to correct the stark imbalances seen in 2021, when high-income nations secured the vast majority of early vaccine doses while low- and middle-income countries were left waiting for months. It establishes a direct, legally binding transaction between the countries that discover new pathogens and the pharmaceutical companies that manufacture the cures.[1][2]

Under the proposed PABS framework, countries are obligated to provide the WHO with rapid, unhindered access to the genetic sequence data of any newly discovered pathogen with pandemic potential. This rapid data sharing is critical for global security; during the COVID-19 pandemic, the quick publication of the SARS-CoV-2 genome allowed scientists around the world to begin developing diagnostic tests and mRNA vaccines within days. The treaty seeks to guarantee that this open flow of information continues without political interference, ensuring that researchers everywhere have the raw materials needed to study emerging threats.[2]

In exchange for this vital data, the treaty imposes binding obligations on pharmaceutical manufacturers who utilize the shared sequences. Participating companies must allocate 20 percent of their real-time production of pandemic-related health products—including vaccines, therapeutics, and diagnostics—to the WHO during a declared emergency. Half of this allocation, or 10 percent of total production, must be donated entirely to the global body. The remaining 10 percent must be sold to the WHO at affordable, at-cost prices for equitable distribution to developing nations. This ensures that life-saving products reach vulnerable populations simultaneously, rather than trickling down only after wealthy nations have stockpiled supplies.[2]

This mandatory benefit-sharing model has triggered intense geopolitical friction. During the May 2025 vote to adopt the overarching agreement, 124 nations voted in favor, but 11 countries abstained. The abstaining bloc included major pharmaceutical manufacturing hubs like Italy, Israel, and the Russian Federation, while the United States notably did not participate in the vote. Their reluctance highlights the deep divide between nations that primarily supply medical innovations and those that rely on importing them. The absence of these key players creates considerable jurisdictional and logistical uncertainty for the global supply chain.[2][3]

Skeptics of the PABS system have raised significant concerns about intellectual property rights, the logistical feasibility of mandatory allocations, and the national security implications of sharing sensitive pathogen data. There are fears that strict mandates could disrupt existing supply chains, violate domestic patent laws, or disincentivize private-sector investment in rapid vaccine development. Some nations argue that forcing companies to surrender a fifth of their production could lead to domestic shortages during a severe crisis, making it politically impossible for elected leaders to support the treaty without facing intense backlash from their own citizens.[2][4]

Conversely, global health advocates argue that the 20 percent allocation is the absolute minimum required to ensure basic global security. They view the PABS system as the moral and practical core of the entire agreement, arguing that without guaranteed access to vaccines and treatments, the treaty's data-sharing requirements merely extract biological resources from developing nations without offering protection in return. For these advocates, the treaty is meaningless without a binding mechanism to enforce equity, as voluntary donation schemes like COVAX proved insufficient during the height of the coronavirus pandemic.[2]

The procedural reality is that the treaty's ultimate fate hinges entirely on the outcome of the July 2026 negotiations in Geneva. Article 31 of the agreement explicitly states that the ratification process cannot begin without the PABS annex. Once the annex is finally adopted, the treaty will require formal ratification by at least 60 member states according to their own constitutional processes before it can officially enter into force. This creates a critical bottleneck: failure to reach consensus on the benefit-sharing mechanism would render the historic 2025 adoption a symbolic but ultimately hollow victory.[2][3]

Negotiators are currently working through highly complex legal definitions, such as what exactly constitutes an 'affordable price' and how traditional knowledge of genetic resources intersects with international patent law. They must also determine how to enforce manufacturer obligations across different legal jurisdictions, especially when key pharmaceutical hubs have expressed reservations. The outcome of these dense technical debates will determine whether the treaty becomes a functional instrument of global equity or simply another set of unfulfilled aspirations that fail to hold up under the pressure of a real-world emergency.[1][2]

If the July deadline is met and the ratifications follow, the WHO Pandemic Agreement will fundamentally reshape the architecture of global health. It promises a future where the genetic code of a dangerous new virus flows freely across borders, and the lifesaving tools built from that code are distributed based on public health need rather than purchasing power. After years of arduous negotiations and millions of lives lost, the world is now just one annex away from institutionalizing the hardest lessons of the COVID-19 era, ensuring that humanity faces the next biological threat united rather than divided.[2]